semaglutide after vsg versus placebo in individuals with poor weight loss bariatric surgery: a double-blinded, randomized, placebo-controlled trial GLP-1 After Gastric Bypass: Safety

Trials of semaglutide published last year caused a stir after they showed patients, on average, lost 16 per cent of their body weight after a year on the drug

Genitourinary Common (1% to 10%): Urinary tract infection, urolithiasis Postmarketing reports : Urolithiasis Hepatic Common (1% to 10%): Cholelithiasis, cholecystitis Uncommon (0.1% to 1%): Increased bilirubin Postmarketing reports : Cholecystitis, cholelithiasis requiring cholecystectomy Hypersensitivity Uncommon (0.1% to 1%): Hypersensitivity Rare (0.01% to 0.1%): Anaphylactic reaction Frequency not reported : Allergic reactions Postmarketing reports : Hypersensitivity, anaphylaxis Hypersensitivity included related adverse events such as rash and urticaria

Good hygiene and staying well-hydrated can reduce this risk

[13] Depending on your age, sex, and symptoms, investigations such as coeliac screening, upper gastrointestinal endoscopy, or colonoscopy may be recommended

Food and Drug Administration (FDA) approves the use of semaglutide for weight loss if you meet one of two criteria

The impact on lifestyle and health was significant, with 97% noticing at least one aspect of their health had improved with weight loss, with increased mobility and improved energy levels often being cited